Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for lanadelumab

  1. Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

    Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over.

    Technology appraisal guidance
    Published
    16 October 2019
    View recommendations

    Sections for TA606

  2. Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)

    Evidence-based recommendations on berotralstat (Orladeyo) for preventing recurrent attacks of hereditary angioedema in people 12 years and older.

    Technology appraisal guidance
    Published
    20 October 2021
    View recommendations

    Sections for TA738